1. Home
  2. TECX vs CTMX Comparison

TECX vs CTMX Comparison

Compare TECX & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$32.34

Market Cap

618.9M

Sector

N/A

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.42

Market Cap

642.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
CTMX
Founded
2019
2008
Country
United States
United States
Employees
60
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
618.9M
642.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
TECX
CTMX
Price
$32.34
$3.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$75.20
$12.10
AVG Volume (30 Days)
150.1K
3.0M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$14.39
$1.72
52 Week High
$39.53
$8.21

Technical Indicators

Market Signals
Indicator
TECX
CTMX
Relative Strength Index (RSI) 57.13 51.97
Support Level $27.30 $3.40
Resistance Level $35.99 $3.96
Average True Range (ATR) 1.50 0.15
MACD 0.16 0.02
Stochastic Oscillator 97.14 78.70

Price Performance

Historical Comparison
TECX
CTMX

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: